AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Recorded Litigation Accrual Reserve by Year
Recorded Litigation Accrual Reserve ($M) ($M)
AbbVie Recorded Litigation Accrual Reserve: $1,600M in FY2025, down 36.0% from a year earlier.
Latest, FY2025
1,600
Period ended Dec 31, 2025
Change on a year earlier
-36.0%
2,500 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-03) ↗
Reported in Form 10-Q / 10-K Legal Proceedings & Contingencies Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Recorded Litigation Accrual Reserve ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,600 | -36.0% | Form 10-Q (filed 2026-08-03) ↗ |
| FY2024 | Dec 31, 2024 | 2,500 | +25.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 2,000 | – | Form 10-K (filed 2025-02-14) ↗ |
Breakdown
What makes up recorded Litigation Accrual Reserve
- Net Litigation Reserve Charges / Adjustments ($M)-933 · FY2025
- Pending Legal Claims — Prescription Opioid Lawsuits Total (cases)335 · FY2025
- Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases)75 · FY2025
- Pending Legal Claims — Other Product Liability Lawsuits (cases)1,320 · FY2025
- Pending Individual Lawsuits — Niaspan Antitrust [annual] (cases)6 · FY2025
Cite this data
StockData. (2026). AbbVie Recorded Litigation Accrual Reserve ($M), annual FY2023–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit-reserve-tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.